Trisomy 13
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
NateraAUSTIN, TX
3 programsBlood DrawN/A
High Risk Multiple Gestation StudyN/A1 trial
Multiple Gestation StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NateraHigh Risk Multiple Gestation Study
NateraMultiple Gestation Study
Human BioSciencesBlood Draw
Clinical Trials (3)
Total enrollment: 1,390 patients across 3 trials
High Risk Multiple Gestation Study
Start: Aug 2014Est. completion: Mar 201999 patients
N/ACompleted
Multiple Gestation Study
Start: Mar 2013Est. completion: Mar 2019354 patients
N/ACompleted
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
Start: Jan 2012Est. completion: Mar 2023937 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.